Immunophenotyping of Acute Leukemia in Pediatric Patients: Tertiary Care Centre Experience from Lahore: Immunophenotyping of Acute Leukemia in Pediatric Patients

Farhana Shahzad; Umaira Ahsan; Aqsa Anam

doi:10.54393/pjhs.v4i09.1012

Authors

Farhana Shahzad Department of Immunology, University of Child Health Sciences & Children’s Hospital, Lahore, Pakistan
Umaira Ahsan Department of Microbiology, Al-Aleem Medical College, Gulab Devi Hospital, Lahore, Pakistan
Aqsa Anam Department of Immunology, University of Child Health Sciences & Children’s Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v4i09.1012

Keywords:

ALL, AML, Immunophenotyping, Flowcytometry, CD markers

Abstract

Acute Leukemia is the most prevalent malignancy of childhood, globally. Immunophenotyping by flowcytometry has developed as an important technique for its outstanding contributions in diagnosis and management of leukemia patients. Objective: To determine the frequency and immunophenotyping by flowcytometry of Acute leukemia in pediatric age group. Methods: The study was conducted at The University of Child health sciences and Children’s Hospital, Lahore from July-2021 to Feb-2022. Data were gathered from 101 consecutive patients, of age from 0.5 to 15 years, that had acute leukemia immunophenotyping using flowcytometry. Results: Flowcytometric immunophenotyping of 101 leukemia patients over 8-month period showed that 67.3% and 33.6% male were females respectively. AML, T-ALL, and B-ALL prevalence was highest in patients with 5 to 10 years of age. Out of 101 leukemia patients, 16 (15.8%) and 85 (84.1%) had AML and ALL diagnosis respectively. Of these 85 ALL cases, 72 (84.7%) were B-ALL and 13 (15.2%) were T-ALL. Study founded that most frequent CD markers in B-ALL, were CD79 and CD19 (100%) whereas CD3 and CD5 in T-ALL and CD13 (93.8%) and CD34 (87.5%) in AML. CD34 was a common marker among B-ALL, T-ALL and AML. Among B-ALL and T-ALL, AntiTdt was a common CD marker whereas HLA-DR was common among AML and B-ALL. Conclusions: Results of Acute leukemia immunophenotyping were homologous to worldwide published research. For accurate leukemia lineage, immunophenotyping of AML and ALL is essential since, if therapy is started based solely on morphological diagnosis, approximately 25% of patients may not respond or recure.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca: A Cancer Journal for Clinicians. 2018 Nov; 68(6): 394-424. doi: 10.3322/caac.21492. DOI: https://doi.org/10.3322/caac.21492

Bispo JA, Pinheiro PS, Kobetz EK. Epidemiology and etiology of leukemia and lymphoma. Cold Spring Harbor perspectives in medicine. 2020 Jun; 10(6): a034819. doi: 10.1101/cshperspect.a034819. DOI: https://doi.org/10.1101/cshperspect.a034819

Tebbi CK. Etiology of acute leukemia: A review. Cancers. 2021 May; 13(9): 2256. doi: 10.3390/cancers13092256. DOI: https://doi.org/10.3390/cancers13092256

Terwilliger T and Abdul-Hay MJ. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer Journal. 2017 Jun; 7(6): e577. doi: 10.1038/bcj.2017.53. DOI: https://doi.org/10.1038/bcj.2017.53

Hakkarainen M, Kaaja I, Douglas SP, Vulliamy T, Dokal I, Soulier J, et al. The clinical picture of ERCC6L2 disease: from bone marrow failure to acute leukemia. Blood, The Journal of the American Society of Hematology. 2023 Jun; 141(23): 2853-66. doi: 10.1182/blood.2022019425. DOI: https://doi.org/10.1182/blood.2022019425

Heuser M, Thol F, Ganser A. Clonal hematopoiesis of indeterminate potential: a risk factor for hematologic neoplasms. Deutsches Ärzteblatt International. 2016 May; 113(18): 317. doi: 10.3238/arztebl.2016.0317. DOI: https://doi.org/10.3238/arztebl.2016.0317

Lagunas-Rangel FA, Chávez-Valencia V, Gómez-Guijosa MÁ, Cortes-Penagos C. Acute myeloid leukemia—genetic alterations and their clinical prognosis. International Journal of Hematology-Oncology and Stem Cell Research. 2017 Oct; 11(4): 328.

Onyije FM, Olsson A, Baaken D, Erdmann F, Stanulla M, Wollschläger D, et al. Environmental risk factors for childhood acute lymphoblastic leukemia: an umbrella review. Cancers. 2022 Jan; 14(2): 382. doi: 10.3390/cancers14020382. DOI: https://doi.org/10.3390/cancers14020382

Puumala SE, Ross JA, Aplenc R, Spector LG. Epidemiology of childhood acute myeloid leukemia. Pediatric Blood & Cancer. 2013 May; 60(5): 728-33. doi: 10.1002/pbc.24464. DOI: https://doi.org/10.1002/pbc.24464

Hossain MG, Islam MN, Islam KM, Jakiyamani M, Chowdhury MA, Khan MR, et al. Frequency of Discrepancy between Bone Marrow Morphology and Immunophenotype in Acute Leukaemia. Haematology. Journal of Bangladesh. 2019; 3(01): 16-9. doi: 10.37545/haematoljbd201929. DOI: https://doi.org/10.37545/haematoljbd201929

Mahto SK and Prasad N. Utility of Flow Cytometry in Diagnosis of Acute Leukemias: A Study at RIMS, Ranchi, India. Journal of Family Medicine and Primary Care. 2022 Nov; 11(11): 7335. doi: 10.4103/jfmpc.jfmpc_1211_21. DOI: https://doi.org/10.4103/jfmpc.jfmpc_1211_21

Narang V, Dhiman A, Garg B, Sood N, Kaur H. Immunophenotyping in Acute leukemias: First tertiary care centre experience from Punjab. Indian Journal of Pathology and Oncology. 2017 Apr; 4(2): 297-300.

Zivarpour P, Hallajzadeh J, Asemi Z, Sadoughi F, Sharifi M. Chitosan as possible inhibitory agents and delivery systems in leukemia. Cancer Cell International. 2021 Dec; 21(1): 1-4. doi: 10.1186/s12935-021-02243-w. DOI: https://doi.org/10.1186/s12935-021-02243-w

Tasian SK, Pollard JA, Aplenc R. Molecular therapeutic approaches for pediatric acute myeloid leukemia. Frontiers in Oncology. 2014 Mar; 4: 55. doi: 10.3389/fonc.2014.00055. DOI: https://doi.org/10.3389/fonc.2014.00055

American Cancer Society. Key Statistics for Childhood Leukemia. 2023. [Last cited: 12th Jan 2023]. Available at: https://www.cancer.org/cancer/types/leukemia-in-children/about/key-statistics.html.

Forsythe A, Breland T, Majumdar S, Elkin TD, Johnson D, Megason G. Gender differences in incidence rates of childhood B-precursor acute lymphocytic leukemia in Mississippi. Journal of Pediatric Oncology Nursing. 2010 May; 27(3): 164-7. doi: 10.1177/1043454209357919. DOI: https://doi.org/10.1177/1043454209357919

Shahab F and Raziq F. Clinical presentations of acute leukemia. Journal of College of Physicians and Surgoens Pakistan. 2014 Jul; 24(7): 472-6.

Arora RS and Arora B. Acute leukemia in children: A review of the current Indian data. South Asian Journal of Cancer. 2016 Jul; 5(03): 155-60. doi: 10.4103/2278-330X.187591. DOI: https://doi.org/10.4103/2278-330X.187591

Shrestha S, Shrestha J, Pun CB, Pathak T, Bastola S, Bhatta R. Immunophenotypic study of acute leukemia by flow cytometry at BPKMCH. Journal of Pathology of Nepal. 2013 Mar; 3(5): 345-50. doi: 10.3126/jpn.v3i5.7856. DOI: https://doi.org/10.3126/jpn.v3i5.7856

Legrand O, Perrot JY, Baudard M, Cordier A, Lautier R, Simonin G, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood, The Journal of the American Society of Hematology. 2000 Aug; 96(3): 870-7. doi: 10.1182/blood.V96.3.870.015k16_870_877. DOI: https://doi.org/10.1182/blood.V96.3.870